Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
59
BOUT Quote, Financials, Valuation and Earnings
Last price:
$39.85
Seasonality move
:
1.49%
Day range:
$39.10 - $40.19
52-week range:
$31.48 - $42.41
Dividend yield:
1.11%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
5.4K
Avg. volume:
3.3K
1-year change:
21.42%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingInnovator IBD Breakout Opportunities ETF has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Innovator IBD Breakout Opportunities ETF has an estimated downside of -- from its current price of $39.85.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -- upside increase from its current price of $39.85.
Fair Value
-
According to the consensus of 0 analysts, Innovator IBD Breakout Opportunities ETF has -- downside to fair value with a price target of -- per share.
BOUT vs. S&P 500
-
Over the past 5 trading days, Innovator IBD Breakout Opportunities ETF has underperformed the S&P 500 by -1.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innovator IBD Breakout Opportunities ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innovator IBD Breakout Opportunities ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Innovator IBD Breakout Opportunities ETF reported revenues of --.
Earnings Growth
-
Innovator IBD Breakout Opportunities ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Innovator IBD Breakout Opportunities ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-24 | 2021-12-24 | 2022-12-24 | 2023-12-24 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BOUT
Sector
Market Cap
--
--
Price % of 52-Week High
--
--
Dividend Yield
1.11%
--
Shareholder Yield
--
--
1-Year Price Total Return
21.42%
--
Beta (5-Year)
0.983
--
Dividend yield:
1.11%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$40.79
200-day SMA
Buy
Level
$36.28
Bollinger Bands (100)
Buy
Level
35.26 - 39.78
Chaikin Money Flow
Buy
Level
89.5K
20-day SMA
Sell
Level
$41.15
Relative Strength Index (RSI14)
Sell
Level
44.93
ADX Line
Sell
Level
0.56
Williams %R
Neutral
Level
-77.4169
50-day SMA
Buy
Level
$39.27
MACD (12, 26)
Buy
Level
0.24
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
337.4K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, BOUT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BOUT average analyst price target in the past 3 months is --.
-
Where Will Innovator IBD Breakout Opportunities ETF Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innovator IBD Breakout Opportunities ETF share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Innovator IBD Breakout Opportunities ETF?
Analysts are divided on their view about Innovator IBD Breakout Opportunities ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innovator IBD Breakout Opportunities ETF is a Sell and believe this share price will rise from its current level to --.
-
What Is Innovator IBD Breakout Opportunities ETF's Price Target?
The price target for Innovator IBD Breakout Opportunities ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BOUT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innovator IBD Breakout Opportunities ETF is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BOUT?
You can purchase shares of Innovator IBD Breakout Opportunities ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innovator IBD Breakout Opportunities ETF shares.
-
What Is The Innovator IBD Breakout Opportunities ETF Share Price Today?
Innovator IBD Breakout Opportunities ETF was last trading at $39.85 per share. This represents the most recent stock quote for Innovator IBD Breakout Opportunities ETF. Yesterday, Innovator IBD Breakout Opportunities ETF closed at $39.85 per share.
-
How To Buy Innovator IBD Breakout Opportunities ETF Stock Online?
In order to purchase Innovator IBD Breakout Opportunities ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.46% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.66% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.53% over the past day.
